[go: up one dir, main page]

MX2024007764A - Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o. - Google Patents

Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o.

Info

Publication number
MX2024007764A
MX2024007764A MX2024007764A MX2024007764A MX2024007764A MX 2024007764 A MX2024007764 A MX 2024007764A MX 2024007764 A MX2024007764 A MX 2024007764A MX 2024007764 A MX2024007764 A MX 2024007764A MX 2024007764 A MX2024007764 A MX 2024007764A
Authority
MX
Mexico
Prior art keywords
treatment
combination
norepinephrine reuptake
task1
sleep apnea
Prior art date
Application number
MX2024007764A
Other languages
English (en)
Inventor
Michael Hahn
Martina Delbeck
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2024007764A publication Critical patent/MX2024007764A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una combinación de bloqueantes selectivos de los canales TASK-1 y TASK-3, en particular derivados sustituidos de imidazo [1,2-a]pirimidina e imidazo [1,2-a]piridina de fórmula (I) e inhibidores de la recaptación de norepinefrina para el tratamiento y/o profilaxis de trastornos respiratorios relacionados con el sueño, preferiblemente apneas obstructivas y centrales del sueño y ronquidos.
MX2024007764A 2021-12-22 2022-12-20 Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o. MX2024007764A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21216885 2021-12-22
PCT/EP2022/086968 WO2023118126A1 (en) 2021-12-22 2022-12-20 Combination of a task1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea

Publications (1)

Publication Number Publication Date
MX2024007764A true MX2024007764A (es) 2024-07-04

Family

ID=79021847

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007764A MX2024007764A (es) 2021-12-22 2022-12-20 Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o.

Country Status (11)

Country Link
US (1) US20250049803A1 (es)
EP (1) EP4452264A1 (es)
JP (1) JP2024545289A (es)
KR (1) KR20240127384A (es)
CN (1) CN118541153A (es)
AU (1) AU2022422284A1 (es)
CA (1) CA3259605A1 (es)
IL (1) IL313648A (es)
MX (1) MX2024007764A (es)
TW (1) TW202342052A (es)
WO (1) WO2023118126A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025082731A1 (en) * 2023-10-20 2025-04-24 Mosanna Therapeutics Ag Intranasal formulations for treating obstructive sleep apnea

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017097671A1 (de) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung
WO2017097792A1 (de) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridin-derivate als blocker der task-1 und task-2 kanäle zur behandlung von schlafbedingten atemstörungen
JOP20190005A1 (ar) 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
GEP20247617B (en) * 2017-04-28 2024-04-25 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
WO2020091862A1 (en) * 2018-10-31 2020-05-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
EP4452264A1 (en) 2024-10-30
CN118541153A (zh) 2024-08-23
KR20240127384A (ko) 2024-08-22
JP2024545289A (ja) 2024-12-05
TW202342052A (zh) 2023-11-01
US20250049803A1 (en) 2025-02-13
AU2022422284A1 (en) 2024-07-04
CA3259605A1 (en) 2023-06-29
IL313648A (en) 2024-08-01
WO2023118126A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
GEP20207104B (en) 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
PH12019500131A1 (en) Substituted diazahetero-bicyclic compounds and their use
GEP20227366B (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
CR10342A (es) INHIBIDORES DE LOS CANALES DE IONES TASK-1 y TASK-3
MY200172A (en) Methods and compositions for treating sleep apnea
AU2017379247A8 (en) Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy
PH12019501458A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
MX2025004365A (es) Metodos y composiciones para el tratamiento de la apnea del sue?o
MX2024007764A (es) Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o.
MY139498A (en) Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
TW200730506A (en) Compounds and uses thereof
MX2021003428A (es) Antagonistas del receptor adrenérgico a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño.
MX2023000369A (es) Combinación de antagonistas del receptor adrenérgico a2 subtipo c (alfa 2c) con un bloqueador de canales task1/3 para el tratamiento de la apnea del sueño.
AU2022298632A1 (en) Methods for treating obstructive sleep apnea
SA521422114B1 (ar) عملية لإنتاج أشكال جرعة صيدلانية تحتوي على مثبطات قناة واستخدامها في علاج اضطراب التنفس task-1 و task-3،
MX2024007884A (es) Combinación de un bloqueador del canal task1/3 con un antagonista del receptor p2x3 para el tratamiento de la apnea del sueño.
MX2024007765A (es) Combinacion de un bloqueante de canal task1/3 con un antagonista del receptor muscarinico para el tratamiento de apnea del sue?o.
MX2024007768A (es) Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o.
MX2021005842A (es) Antagonistas de los adrenoreceptores a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño.
MX2008011204A (es) 1-amino-4-fenil-dihidroisoquinolinas sustituidas, metodo para su produccion, su uso como medicamento, y medicamentos que las contienen.
MX2024008522A (es) Derivados de 2,3-dihidrobenzo[b][1,4]dioxin-2-ilmetil)piperazin-1- ilo para el tratamiento de la apnea del sue?o.
MX2024008523A (es) Antagonistas del adrenoceptor a2 subtipo c para el tratamiento de la apnea del sue?o.
EA201990341A1 (ru) Замещенные диазагетеробициклические соединения и их применение